FDA Approves Tibsovo for Acute Myeloid Leukemia
MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene.
Tibsovo ' s effectiveness was...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Food and Drug Administration (FDA) | Genetics | Leukemia | Pharmaceuticals